<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002818.pub2" GROUP_ID="MS" ID="683500042617292757" MERGED_FROM="" MODIFIED="2008-10-28 11:17:29 +0100" MODIFIED_BY="Liliana Coco" REVIEW_NO="Edit" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-10-28 11:14:34 +0100" MODIFIED_BY="Liliana Coco">
<TITLE>Amantadine for fatigue in multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="14870" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eugenio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pucci</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>eugenio_pucci@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>347-2304548</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>U.O. Neurologia - Ospedale di Macerata</DEPARTMENT>
<ORGANISATION>ASUR Marche - Zona Territoriale 9</ORGANISATION>
<ADDRESS_1>Via Santa Lucia, 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Macerata</CITY>
<ZIP>62100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-0733-257844</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-28 11:14:34 +0100" MODIFIED_BY="Liliana Coco">
<PERSON ID="14870" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eugenio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pucci</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>eugenio_pucci@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>347-2304548</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>U.O. Neurologia - Ospedale di Macerata</DEPARTMENT>
<ORGANISATION>ASUR Marche - Zona Territoriale 9</ORGANISATION>
<ADDRESS_1>Via Santa Lucia, 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Macerata</CITY>
<ZIP>62100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-0733-257844</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14839" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pedro</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brañas Tato</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant</POSITION>
<EMAIL_1>pedro.branas.tato@sergas.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology</DEPARTMENT>
<ORGANISATION>Conselleria de Sanidade SERGAS</ORGANISATION>
<ADDRESS_1>San Lazaro</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago de Compostela</CITY>
<ZIP>15703</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 881 542916</PHONE_1>
<PHONE_2/>
<FAX_1>+34 881 542970</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11485" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>D'Amico</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>damico.roberto@unimore.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oncology and Hematology</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1>Via del Pozzo 71</ADDRESS_1>
<ADDRESS_2/>
<CITY>Modena</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 059 4223865</PHONE_1>
<PHONE_2/>
<FAX_1>+39 059 2055483</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14853" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giorgio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Giuliani</LAST_NAME>
<SUFFIX/>
<POSITION>Direttore U.O. Neurologia</POSITION>
<EMAIL_1>giulineu@libero.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medicina</DEPARTMENT>
<ORGANISATION>Ospedale di Macerata</ORGANISATION>
<ADDRESS_1>Via Santa Lucia, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Macerata</CITY>
<ZIP>62100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>339 4439350</PHONE_1>
<PHONE_2>071 33026</PHONE_2>
<FAX_1>0733 2572825</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6361" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Alessandra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solari</LAST_NAME>
<SUFFIX/>
<POSITION>MD (Neurologist)</POSITION>
<EMAIL_1>solari@istituto-besta.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. - Neurological Institute Carlo Besta</ORGANISATION>
<ADDRESS_1>Via Celoria 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-02-2394 2391</PHONE_1>
<PHONE_2/>
<FAX_1>+39-02-70638217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14877" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cristiana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Taus</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>cristianataus@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unità Operativa di Neurologia</DEPARTMENT>
<ORGANISATION>Ospedale San Salvatore</ORGANISATION>
<ADDRESS_1>Piazzale Cinelli,4</ADDRESS_1>
<ADDRESS_2/>
<CITY>Pesaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-0721-362390</PHONE_1>
<PHONE_2>+39-347-3652132</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-20 11:00:02 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="15" MONTH="11" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="7" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-11 10:34:13 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="20" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-11 10:34:45 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 10:34:45 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="29" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>searches were re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Marche SM-ONLUS</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-11 10:37:22 +0200" MODIFIED_BY="Liliana Coco">
<SUMMARY MODIFIED="2008-08-20 11:02:31 +0200" MODIFIED_BY="Liliana Coco">
<TITLE MODIFIED="2008-08-20 11:02:31 +0200" MODIFIED_BY="Liliana Coco">The effect of amantadine for the treatment of fatigue in people with multiple sclerosis</TITLE>
<SUMMARY_BODY>
<P>Multiple sclerosis (MS) is a chronic disease affecting young and middle-aged adults. One of the most common and disabling symptoms of MS is fatigue. Different approaches have been used to try and improve this, including energy conservation, specialised fitness training and drug treatments. Amantadine has been used to try to relieve fatigue in MS. This review found that Amantadine efficacy in reducing MS-related fatigue and its tolerability are poorly documented and more research is needed. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-26 12:49:49 +0200" MODIFIED_BY="Deirdre Beecher">
<ABS_BACKGROUND>
<P>Fatigue is one of the most common and disabling symptoms of people with Multiple Sclerosis (MS). The effective management of fatigue has an important impact on the patient's functioning, abilities, and quality of life. Although a number of strategies have been devised for reducing fatigue, treatment recommendations are based on a limited amount of scientific evidence. Many textbooks report amantadine as a first-choice drug for MS-related fatigue because of published randomised controlled trials (RCTs) showing some benefit. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness and safety of amantadine in treating fatigue in people with MS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-26 12:49:49 +0200" MODIFIED_BY="Deirdre Beecher">
<P>We searched The Cochrane MS Group Trials Register (July 2006), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to July 2006), EMBASE (January 1974 to July 2006), bibliographies of relevant articles and handsearched relevant journals. We also contacted drug companies and researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Three reviewers selected studies for inclusion in the review and they extracted the data reported in the original articles. We requested missing and unclear data by correspondence with the trial's principal investigator. A meta-analysis was not performed due to the inadequacy of available data and heterogeneity of outcome measures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Out of 13 pertinent publications, 5 trials met the criteria for inclusion in this review: one study was a parallel arms study, and 4 were crossover trials. The number of randomised participants ranged between 10 and 115, and a total of 272 MS patients were studied. Overall the quality of the studies considered was poor and all trials were open to bias. All studies reported small and inconsistent improvements in fatigue, whereas the clinical relevance of these findings and the impact on patient's functioning and health related quality of life remained undetermined. The number of participants reporting side effects during amantadine therapy ranged from 10% to 57%.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The efficacy of amantadine in reducing fatigue in people with MS is poorly documented, as well as its tolerability. It is advisable to: (1) improve knowledge on the underlying mechanisms of MS-related fatigue; (2) achieve an <BR/>agreement on accurate, reliable and responsive outcome measures of fatigue; (3) perform good quality RCTs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-11 10:37:22 +0200" MODIFIED_BY="Liliana Coco">
<BACKGROUND>
<P>Fatigue is one of the most common and disabling symptoms of Multiple Sclerosis (MS). Between 76% and 92% of people with MS report fatigue and between 55% and 75% of them consider fatigue one of the most debilitating symptoms (<LINK REF="REF-Krupp--1997" TYPE="REFERENCE">Krupp 1997</LINK>]). Fatigue can be defined as a sense of tiredness or lack of energy greater than expected for the daily effort and degree of disability. Difficulty exists in the clinical assessment of fatigue. Patient's self report is considered the most appropriate evaluation modality since it takes into account the fatigue-related changes in functioning according to patient's direct experience (<LINK REF="REF-Krupp--1997" TYPE="REFERENCE">Krupp 1997</LINK>). Although many tools have been devised, up to now no validated scale has been used with unanimous consent. </P>
<P>Different pathophysiological mechanisms, either peripheral or central, have been suggested for fatigue associated with MS. Some of these mechanisms or other mechanisms can be responsible for fatigue linked to the use of drugs (e.g. interferons, steroids, immunosuppressive agents, benzodiazepines, and anti-spasticity agents), or concomitant diseases (e.g. chronic infections).<BR/>Amantadine is an anti-influenza agent as it inhibits replication of influenza A viruses (<LINK REF="REF-Hayden-1996" TYPE="REFERENCE">Hayden 1996</LINK>). However, the use of amantadine has been discouraged in seasonal and pandemic influenza in a recent systematic review (<LINK REF="REF-Jefferson-2006a" TYPE="REFERENCE">Jefferson 2006a</LINK>; <LINK REF="REF-Jefferson-2006b" TYPE="REFERENCE">Jefferson 2006b</LINK>). Amantadine may be effective as an adjunct to interferon-based combination therapy in patients with chronic hepatitis C (<LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>). Its dopaminergic effect was discovered after serendipitous evidence of improvement in symptoms of Parkinson's disease (<LINK REF="REF-Schwab-1972" TYPE="REFERENCE">Schwab 1972</LINK>). Similarly, the first evidence of improved fatigue in MS was from a patient treated with amantadine for influenza prophylaxis (<LINK REF="STD-Murray-1985" TYPE="STUDY">Murray 1985</LINK>). Activity on glutamate receptors has also been shown (<LINK REF="REF-Stoof-1992" TYPE="REFERENCE">Stoof 1992</LINK>).</P>
<P>The mechanism of the potential action of amantadine for fatigue remains unclear. An antiviral activity, an immunologically mediated action (<LINK REF="REF-Bertolone-1993" TYPE="REFERENCE">Bertolone 1993</LINK>), or an amphetamine-like action have been suggested (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>; <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>).</P>
<P>Since 1987, some benefits of amantadine have also been reported by randomised, double-blind, placebo controlled trials (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>; <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>; <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). As a consequence, many textbooks report amantadine as a first-choice drug for MS-related fatigue. </P>
<P>A non systematic narrative overview on amantadine in MS-related fatigue was published in 1993 by Kemp and Gora (<LINK REF="STD-Kemp-1993" TYPE="STUDY">Kemp 1993</LINK>). Another overview based on a literature review including several databases (MEDLINE, CINAHL, Nursing and Allied Health literature Index, ClinPSYC) has been published by a panel of experts (<LINK REF="REF-Anonymous-1998" TYPE="REFERENCE">Anonymous 1998</LINK>). The latter concluded that approximately 20 to 40% of mildly to moderately disabled people with MS showed significant short-term reduction in fatigue with amantadine therapy, which was well tolerated. A "rapid review" on treatment for fatigue in MS (<LINK REF="REF-Branas-2000" TYPE="REFERENCE">Branas 2000</LINK>), with a wide section for amantadine treatment, showed inconclusive results.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objectives of this review were to assess the efficacy and safety of amantadine in reducing fatigue in people with MS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-11 10:37:22 +0200" MODIFIED_BY="Liliana Coco">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Double-blind, randomised, controlled trials (RCTs) and crossover trials were included. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients diagnosed as having clinically definite or probable MS according to Schumacher (<LINK REF="REF-Schumacher-1965" TYPE="REFERENCE">Schumacher 1965</LINK>), Poser (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>) or McDonald criteria (<LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>), and also reporting fatigue. No strict definition of fatigue was required.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Amantadine hydrochloride versus placebo or other drugs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>(1) FATIGUE SPECIFIC <BR/>(a) Patient's subjective response (dichotomous outcome: better versus worse or not changed)<BR/>(b) Changes in validated scales for fatigue assessment (continuous outcomes)<BR/>(2) GLOBAL OUTCOMES - DISEASE SPECIFIC<BR/>Changes in Expanded Disability Status Scale (EDSS) (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>), Ambulation Index (AI) (<LINK REF="REF-Hauser-1983" TYPE="REFERENCE">Hauser 1983</LINK>), Multiple Sclerosis Functional Composite (MSFC) (<LINK REF="REF-Fischer-1999" TYPE="REFERENCE">Fischer 1999</LINK>) and MS-specific health related quality of life questionnaires were considered as continuous outcomes<BR/>(3) GLOBAL OUTCOMES - NON DISEASE SPECIFIC <BR/>(a) Changes in non MS-specific disability or health related quality of life scales (continuous outcomes)<BR/>(b) Willingness to continue treatment<BR/>(4) SAFETY - ADVERSE EFFECTS<BR/>Safety and tolerability were assessed from the number of dropouts and adverse events (dichotomous outcomes). Adverse events were categorised into (i) mild-moderate and (ii) major events (death, or any event requiring hospitalisation or medical intervention).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-11 10:37:22 +0200" MODIFIED_BY="Liliana Coco">
<ELECTRONIC_SEARCHES MODIFIED="2008-09-11 10:37:06 +0200" MODIFIED_BY="Liliana Coco">
<P>We searched The Cochrane MS Group trials register (July 2006), The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2, 2006)(<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (PUBMED) (January 1966 to July 2006)(<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) (January 1974 to July 2006).<BR/>In addition, we used the following methods:</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-11 10:37:15 +0200" MODIFIED_BY="Liliana Coco">
<P>In addition, we used the following methods:<BR/>(1) screening of reference lists of all available review articles and primary studies found;<BR/>(2) handsearch of the abstract book of recent symposia of European Committed Therapies and Rehabilitation in MS (from 1993 to 2002), Italian Neurological Society (from 1990 to 2002), European Federation of Neurological Sciences (from 1996 to 2002), and American Academy of Neurology (from 1997 to 2002);<BR/>(3) personal contact with corresponding authors of relevant trials or reviews, and other MS experts;<BR/>(4) contact and inquiry of drug manufactures of amantadine.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two reviewers (CT and EP) independently decided whether the identified papers were pertinent for the review by reading their abstracts. Once the studies were judged pertinent, three reviewers (CT, AS, EP) independently read the full texts, and decided which studies to include. </P>
<P>Only the RCTs scoring A (adequate allocation concealment) or B (unclear allocation concealment) according to the Cochrane Collaboration quality assessment criteria (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) were considered eligible for this review. Quality of RCTs was assessed through Jadad's scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The scale consists of 3 items: description of randomisation, blinding and attrition. The possible range of this scale score is between 0 (worst) and 5 (best).<BR/>For randomisation, two points were given for randomised studies in which randomisation method was described and adequate; one point was given for randomised studies in which randomisation method was not described. <BR/>For blinding, two points were given to double blind studies in which concealment method was described and adequate, one point for double blind studies not describing concealment method. One point was given if information on attrition was reported. A quality scale for crossover trials was also devised, consisting of Jadad's scale items and one adjunctive item regarding the washout period: one point was deducted from the Jadad's score if the washout period was not described, there was no washout period, or the washout was described and judged inappropriate by the rater. <BR/>The scoring for allocation concealment and the Jadad's scale were rated by three reviewers (CT, AS, EP). Disagreement among reviewers was discussed and resolved, where possible, by consensus. Otherwise a decision was achieved by the vote of the majority.<BR/>The principal investigator of each trial was contacted to obtain information about the results of each (or at least the first) study period and in particular if there was missing or unclear data.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>See table of included studies for details.<BR/>We identified 13 publications pertinent to the review through electronic and manual searches. After reading the full published text, we excluded eight articles: one was a narrative overview (<LINK REF="STD-Kemp-1993" TYPE="STUDY">Kemp 1993</LINK>); four were non randomised studies (<LINK REF="STD-Murray-1985" TYPE="STUDY">Murray 1985</LINK>; <LINK REF="STD-Plaut-1987" TYPE="STUDY">Plaut 1987</LINK>; <LINK REF="STD-Maciejek-1989" TYPE="STUDY">Maciejek 1989</LINK>; <LINK REF="STD-Chiba-1992" TYPE="STUDY">Chiba 1992</LINK>) one study (two publications) considered only para-clinical endpoints (<LINK REF="STD-Sailer-1996" TYPE="STUDY">Sailer 1996</LINK>; <LINK REF="STD-Sailer-2000" TYPE="STUDY">Sailer 2000</LINK>), and one study was a duplicate publication of a study included in the present review (<LINK REF="STD-Geisler-1996" TYPE="STUDY">Geisler 1996</LINK>). No unpublished trials were identified by our search procedures. Thus 5 trials met the criteria for inclusion in this review (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>; <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>; <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>; <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). These trials were published between 1987 and 2004.</P>
<P>
<B>Methods and interventions</B>
<BR/>Two studies compared Amantadine versus other drugs: (i) a three-arm parallel trial comparing six-week treatment with amantadine (100 mg b.d.i), pemoline, or placebo (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>); (ii) a 3 months crossover trial of amantadine versus acetyl L-carnitine (<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). The other three studies were crossover RCTs (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>; <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>; <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>) designed to compare amantadine (100 mg b.i.d) with placebo. The length of each treatment phase ranged between 1 week and 3 months, and the length of the washout phase ranged between 1 and 2 weeks.<BR/>Two studies had a 2 week run-in period in which participants were monitored to determine fatigue severity (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). </P>
<P>
<B>Participants</B>
<BR/>All but one study (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>) included participants with probable or definite MS according to pre-specified criteria, and complaining of moderate to severe fatigue. The study from Rosenberg et al. did not specify the diagnostic criteria considered, and included patients with anamnestic fatigability (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>). <BR/>Regarding severity of fatigue at enrolment, the Canadian trial included participants who, in the run-in period, scored 25 mm or above on a 50 mm visual analogue scale (VAS) ranging between "no fatigue" (0) and "as bad as could be" (50) (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>). <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK> considered eligible MS people scoring 80 or over in the Fatigue Assessment Inventory-based (FAI) scale. The FAI score is a patient's self assessed fatigue inventory developed by the authors, made of 42 items, each scoring from 1 (not at all) to 4 (very representative). The maximum possible score is 168 (<LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>). The parallel trial comparing 6-week treatment with amantadine, pemoline, or placebo (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>) included patients with a baseline Fatigue Severity Scale (FSS) (<LINK REF="REF-Krupp1989" TYPE="REFERENCE">Krupp1989</LINK>) score of 4.0 or more. <BR/>All studies but one (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>) excluded people with severe depression and with significant other medical comorbidities, and people taking fatigue inducing drugs. In particular, as far as the <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study is concerned, patients should have been under Interferon beta treatment for at least 1 year in order to avoid occurrence of fatigue which was considered to occur more frequently in the early phase of such a treatment. <BR/>Overall, the number of randomized patients ranged between 10 and 115 (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>
<B>Outcome measures</B>
<BR/>The studies used different methods to measure fatigue. The most frequently reported outcome was participant's preference, or his subjective impression of benefit. The <LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK> considered as efficacy end-points the preferred treatment period by the patient and the physician. Furthermore, participants recorded their daily fatigue experience on a 50 mm VAS ranging between "no fatigue" and "as bad as could be". <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK> considered as a unique end point patient's drug preference. <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK> reported both patient's preference and changes in a fatigue scale developed by the authors which consisted of the following seven indices for fatigue: energy, muscle strength, concentration/memory, motivation, ability to finish a task, problem solving, and well being. Each item was scored on a five point scale, ranging from one (poor) to five (excellent). The parallel trial considered three efficacy end-points: the MS-Specific Fatigue Scale (MS-FS) (<LINK REF="REF-Schwartz-1993" TYPE="REFERENCE">Schwartz 1993</LINK>), the FSS (<LINK REF="REF-Krupp1989" TYPE="REFERENCE">Krupp1989</LINK>), and the patient's verbal reports (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). Both fatigue scales were clinically validated. The MS-FS is a disease-specific six-item inventory, and the FSS a non MS-specific nine-item global measure of the effect of fatigue on daily living.<BR/>In the <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study the primary efficacy measure was the FSS (<LINK REF="REF-Krupp1989" TYPE="REFERENCE">Krupp1989</LINK>); a secondary efficacy measure was the Fatigue Impact Scale - FIS - (<LINK REF="REF-Fisk-1994" TYPE="REFERENCE">Fisk 1994</LINK>). The FIS is a non MS-specific 40-item tool (score ranging 0-4 for each item) which allows a multidimensional evaluation (cognitive, physical, social role and psychological). It was not validated at the time of the Tomassini 2004 study. Nowadays, studies which validate versions of the FIS (or modified-versions) have been published (<LINK REF="REF-Mathiowetz-2003" TYPE="REFERENCE">Mathiowetz 2003</LINK>; <LINK REF="REF-Hauser-2003" TYPE="REFERENCE">Hauser 2003</LINK>; <LINK REF="REF-Flensner-2005" TYPE="REFERENCE">Flensner 2005</LINK>; <LINK REF="REF-Kos-2005" TYPE="REFERENCE">Kos 2005</LINK>; <LINK REF="REF-Pittion_x002d_Vouyovitch06" TYPE="REFERENCE">Pittion-Vouyovitch06</LINK>).<BR/>All the trials reported the number of side effects and drop outs, except for the <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study in which the prevalence of side-effects was not separately reported.<BR/>None of the crossover trials gave data on each study period. We contacted the principal investigators of all the included RCTs for further information, and an extraction form was also enclosed to facilitate data provision. We have so far received apologetic answers of inability to give information from the authors of two studies (<LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>; <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). Thus this review was carried out on the basis of data available in the original published papers.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>See table of included studies for details.</P>
<P>All trials were reported as randomised. All but one included study met category B of the criteria of randomisation. Only one study described the method of randomization as computer-generated (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>).The <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study was ranked B notwithstanding the Authors' personal communication about the fact that randomization was computer-generated. <BR/>All trials were reported as conducted in a "double-blind" fashion. Two studies partially described the method of blinding (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). Allocation concealment following randomization and masking of outcome assessment were not specified in any included RCTs. All trials obtained a score of 3 on Jadad's scale (or modified Jadad's scale for crossover trial).<BR/>
<BR/>The number of drop outs was reported by all the included trials. In Rosenberg's trial all 10 randomised participants completed both study periods (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>). The percentage of drop outs reported by the Canadian trial was 8.5%, though 21 out of 115 randomised participants were excluded from the analysis since their level of fatigue did not fulfil the eligible criteria. The resulting percentage of randomised participants which were not analysed was 25% (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>). The percentage lost to follow up reported by the parallel study was 22% (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK> reported a similar percentage (24%). Six patients withdrew from the <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study because of adverse reactions.<BR/>Information on intention to treat analysis for the main outcomes was not available in the original papers, and most continuous outcomes figures were discussed but not reported in detail in the tables or in the text. <BR/>A washout period was present in all crossover trials, and its duration (from 1 week to 3 months) seems sufficient to avoid a carry over effect of amantadine. However, it was not possible to verify this hypothesis since separate data from each study period were universally lacking in the original publications, nor were they provided on our request by the authors. In one study only, the authors attempted to verify the potential occurrence of a period effect (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>). In one study only, the carry over effect was taken into consideration, through evaluating washout differences against the null hypotheses of no change during washout periods (<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>A total of 190 patients were randomized (and 148 analysed in the original papers) in crossover studies, with figures ranging from 10 to 115. Out of 109 patients randomized in the parallel-arm trial, 39 received amantadine, 27 pemoline, and 43 placebo. The effect of amantadine on overall subjective improvement was reported by all the included trials except for the <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> study, but we could not summarize results since data for each study period were not available for the crossover studies.<BR/>In the Canadian trial 35 out of 115 randomised participants (30%) preferred the amantadine phase while 51 of them (44%) preferred other trial phases: 18 patients (16%) preferred the placebo phase, 5 (4%) the washout phase, and 28 (24%) did not express any preference (<LINK REF="STD-CMSRG-1987" TYPE="STUDY">CMSRG 1987</LINK>). In <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK> at the end of the study there were six responder patients (60%), i.e. participants who preferred amantadine, versus 4 (40%) non responders (one participant preferred placebo and three had not preference). In <LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>, 8 out of 29 randomized patients (28%) preferred amantadine, 4 (14%) preferred placebo, and 10 (34%) did not express any preference. Krupp et al. assessed the benefit perceived by the participant at the end of treatment and two weeks later (post-treatment follow up) (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). Thirteen out of 39 participants assigned to amantadine (33%) perceived benefit while on the drug, while 15 (38%) perceived benefit at post-treatment follow up. Fourteen out of 43 of those assigned to placebo (32%) had benefit while on placebo, and 13 (30%) at post-treatment follow up. The results of continuous outcomes for each trial correspond to those available in the original papers, and are reported in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. <BR/>The number of participants reporting side effects during amantadine treatment was overall 40% (ranging from 10% to 57%) versus 35.5% during placebo treatment. <BR/>Overall no major events were reported, side effects were generally mild, and included hallucinations, nausea, dizziness, hyperactivity, anxiety, and insomnia. However, in one study the drop-out rate because of side effects was about 28% (5/18) (<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). <BR/>No synthesized results are given due to large heterogeneity in outcome measures between trials, and incomplete data, such as information on each separated study phase for crossover studies (<LINK REF="REF-Curtin-2002-A" TYPE="REFERENCE">Curtin 2002 A</LINK>; <LINK REF="REF-Curtin-2002-B" TYPE="REFERENCE">Curtin 2002 B</LINK>). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Overall the methodological quality of the studies considered was poor. Data and methods reported in the original papers were not described by the authors with sufficient detail. All the crossover studies did not report data from each (or at least the first) treatment period separately. The results for many continuous outcome measures considered were reported incompletely (for some outcomes only p-values were given) or in different ways so that it was not possible to estimate the treatment effect. Despite attempts to contact principal investigators, we were unable to obtain the data necessary to perform a combined analysis. Overall the percentage of patients who preferred amantadine was low in all but one study (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>) performed on a small sample of patients. In one study, authors concluded that amantadine was less tolerated and less effective than acetyl L-carnitine for the treatment of MS-related fatigue (<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). <BR/>A high percentage of patients lost to follow-up was observed. The studies reported inconsistent results and the clinical relevance of them and the impact on patient's functioning and health related quality of life remains undetermined.<BR/>As far as the tolerability is concerned, it must be reported that some reviews about the use of amantadine in different diseases provide some doubts about its tolerability. In particular, the authors of two Cochrane reviews on Parkinson disease (<LINK REF="REF-Crosby-2003a" TYPE="REFERENCE">Crosby 2003a</LINK>; <LINK REF="REF-Crosby-2003b" TYPE="REFERENCE">Crosby 2003b</LINK>), claim about the tolerability of amantadine saying that rigorous analysis of selected RCTs reveals insufficient evidence of its safety (and of its efficacy in Parkinson disease). The authors of a Cochrane review on influenza A therapy state that amantadine induces significant gastrointestinal adverse effects and that some study withdrawals have to be related to adverse effects of the central nervous system (CNS) (<LINK REF="REF-Jefferson-2006a" TYPE="REFERENCE">Jefferson 2006a</LINK>; <LINK REF="REF-Jefferson-2006b" TYPE="REFERENCE">Jefferson 2006b</LINK>). Finally, in a recent review about influenza (<LINK REF="REF-Kamps-2006" TYPE="REFERENCE">Kamps 2006</LINK>), CNS side effects (dizziness, nervousness, agitation, difficulty concentrating, insomnia, and lowered seizure threshold) are reported to occur in a substantial number of patients treated with amantadine, in particular: in a four-week prophylaxis trial, these symptoms occurred in up to 33 % of young individuals (<LINK REF="REF-Bryson-1980" TYPE="REFERENCE">Bryson 1980</LINK>); in another trial, 13% patients receiving amantadine withdrew from the study because of CNS side effects (<LINK REF="REF-Dolin-1982" TYPE="REFERENCE">Dolin 1982</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Due to the poor methodological quality and limited clinical relevance of findings, straightforward recommendations for practice cannot be made. Overall there is no evidence supporting the use of amantadine.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The insufficient quality of the available studies warrants further research. Trials on amantadine or other intervention for MS-related fatigue definitely need adequate sample sizes, parallel arms randomized controlled designs, as well as clinically relevant, reliable and responsive outcome measures. The definition of MS-related fatigue should be better specified. Furthermore future trials should follow specific guidelines concerning the inclusion criteria, control of co-interventions and co-morbidities, and should follow internationally published guidelines for reporting trials. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We acknowledge the contribution of Dr Chris Hyde to the first version of the review.<BR/>Authors wish to thank the consumers R. Pacetti, C. Ortensi, J. Bartolacci, M. Diamanti from the "Associazione Italiana Sclerosi Multipla (AISM) - Sede Provinciale di Macerata", who read the abstract and the reviewers' conclusions in order to have some consumers' comments to the comprehension of the draft versions and the final version of these sections of this review.<BR/>The authors wish to thank L. Coco and V. Pistotti of the Cochrane Multiple Sclerosis Group for their assistance and G. Ferrari (from C. Besta National Neurological Institute) and J. Bartolacci (from "SM Marche Network") for their secretary help.<BR/>The authors wish also to thank "Marche-SM ONLUS" which supported the updating of this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>GG and AS first had the idea of systematically reviewing data on amantadine therapy in MS-related fatigue. They designed the protocol for the first time, with the help of CT and EP.<BR/>CT and EP independently decided whether the identified papers were pertinent for the review by reading their abstracts. CT, AS and EP independently read the full texts, and decided which studies to include; BP participated in that process in the previous version of the review.<BR/>RD gave methodological and statistical advice.<BR/>All the authors gave some contributions in writing the present and the previous versions; the latter was mainly prepared by CT and EP. The principal responsible for preparing the present version was EP.<BR/>Dr C. Hyde contributed to preparing the previous version of this review. He was not able to participate in the present update.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-21 11:47:28 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-CMSRG-1987" NAME="CMSRG 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;The Canadian MS Research Group. A Randomized Controlled Trial of Amantadine in Fatigue Associated Whit Multiple Sclerosis. Can J Neurol Sci 1987; 14:273-278&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Canadian MS Research Group</AU>
<TI>A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>3</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1989" NAME="Cohen 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Cohen RA, Fisher M. Amantadine treatment of fatigue associated with Multiple Sclerosis. Arch Neurol 1989; 46:676-680&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RA, Fisher M</AU>
<TI>Amantadine treatment of fatigue associated with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>6</NO>
<PG>676-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krupp-1995" NAME="Krupp 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in Multiple Sclerosis: results of a double-blind, randomized, parallel trial of Amantadine, Pemoline and Placebo. Neurol 1995; 45:1956-1961&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al</AU>
<TI>Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine pemoline, and placebo</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>11</NO>
<PG>1956-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenberg-1988" NAME="Rosenberg 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Rosenberg GA, Appenzeller O. Amantadine, fatigue and Multiple Sclerosis. Arch Neurol 1988; 45:1104-1106&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg GA, Appenzeller O</AU>
<TI>Amantadine, fatigue and multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>10</NO>
<PG>1104-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomassini-2004" NAME="Tomassini 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C</AU>
<TI>Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2004</YR>
<VL>218</VL>
<PG>103-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiba-1992" NAME="Chiba 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Chiba S, Ito M, Matsumoto H. Amantadine treatment for refractory pain and fatigue in patients whit multiple sclerosis. Can J Neurol Sci 1992; 19:309&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chiba S, Ito M, Matsumoto H</AU>
<TI>Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>2</NO>
<PG>309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geisler-1996" NAME="Geisler 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Geiser MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of Amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996;53: 185-188&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB</AU>
<TI>The effects of amantadine and pemoline on cognitie functioning in multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>2</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-1993" NAME="Kemp 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Kemp BA, Gora ML. Amantadine and Fatigue in Multiple Sclerosis. Ann Pharmacotherapy 1993;27(7-8):893-895&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemp Ba, Gora ML</AU>
<TI>Amantadine and Fatigue of Multiple Sclerosis</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>1993</YR>
<VL>27</VL>
<NO>7-8</NO>
<PG>893-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maciejek-1989" NAME="Maciejek 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Maciejek Z. Changes in visual evoked potentials in patients with multiple sclerosis trated with isoprinosine and amantadine. Archivium Immunologiae et Therapy Experimentalis 1989;37:621-628&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maciejek Z</AU>
<TI>Changes in visual ovoked potentials in patients with multiple sclerosis treated with isoprinosine and amantadine</TI>
<SO>Archivum Immunologiae et Therapiae Experimentalis</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>5-6</NO>
<PG>621-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murray-1985" NAME="Murray 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Murray TJ. Amantadine Therapy for Fatigue in Multiple Sclerosis. Can J Neurol 1985; 12:251-254&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Murray TJ</AU>
<TI>Amantadine therapy for fatigue in multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1985</YR>
<VL>15</VL>
<NO>3</NO>
<PG>251-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plaut-1987" NAME="Plaut 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Plaut GS. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J Royal Soc Med 1987;80:91-93&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plaut GS</AU>
<TI>Effectiveness of amantadine in reducing relapses in multiple sclerosis</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1987</YR>
<VL>80</VL>
<NO>2</NO>
<PG>91-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sailer-1996" NAME="Sailer 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Sailer M, smid HGOM, Schoenfeld A, Hauser U, Heinze HJ. Effect of amantadine on cognitive processes in multiple sclerosis patients with fatigue: a double-blind placebo controlled cross-over study.  European J Neurol 1996;3 (Suppl 4):61-62 (Abstract)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sailer M, Smid HOGM, Schoenfeld A, Hauser U, Heinze Hj</AU>
<TI>Effect of amantadine on cognitive processes in multiple sclerosis with fatigue: A double-blind placebo controlled cross-over study</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<VL>3 Suppl (4)</VL>
<PG>61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sailer-2000" NAME="Sailer 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Sailer M, Heinze Hi, Schoenfeld MA, Hauser U, Smid HG. Amantadine influences cognitive processing in patient with multiple sclerosis. Pharmacopsychiatry 2000;33:28-37&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sailer M, Heinze Hi, Schoenfeld MA, Hauser U, Smid HG</AU>
<TI>Amantidine influences cognitive processing in patients with multiple sclerosis</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>1</NO>
<PG>28-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-21 11:47:28 +0200" MODIFIED_BY="Deirdre Beecher">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-21 11:47:28 +0200" MODIFIED_BY="Deirdre Beecher">
<REFERENCE ID="REF-Anonymous-1998" MODIFIED="2008-08-20 11:10:40 +0200" MODIFIED_BY="Liliana Coco" NAME="Anonymous 1998" TYPE="BOOK_SECTION">
<AU>Multiple Sclerosis Council for Clinical Practice Guidelines</AU>
<TI>Fatigue and Multiple Sclerosis. Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis</TI>
<SO>Clinical Practice Guidelines</SO>
<YR>1998</YR>
<PB>Multiple Sclerosis Council for Clinical Practice Guidelines</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1961" MODIFIED="2008-08-20 13:51:07 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Beck 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Ward CH, Medelson M, Mock JE, Mohr DC, Erbaugh JK</AU>
<TI>An inventory for measuring depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>567-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertolone-1993" MODIFIED="2008-08-21 11:47:28 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bertolone 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bertolone K, Coyle PK, Krupp LB, Doscher CA</AU>
<TI>Cytokine correlates of fatigue in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>4 Suppl 2</NO>
<PG>A356</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Branas-2000" MODIFIED="2008-08-20 13:43:23 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Branas 2000" TYPE="JOURNAL_ARTICLE">
<AU>Branas P, Jordan R, Fry-Smith A, Burls A, C Hyde</AU>
<TI>Treatments for fatigue in multiple sclerosis: a rapid and systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>27</NO>
<PG>1-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryson-1980" MODIFIED="2008-08-20 13:50:15 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bryson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bryson YJ, Monahan C, Pollack M, Shields WD</AU>
<TI>A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>141</VL>
<PG>543-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crosby-2003a" MODIFIED="2008-08-20 13:38:02 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Crosby 2003a" TYPE="COCHRANE_REVIEW">
<AU>Crosby N, Deane KHO, Clarke CE.</AU>
<TI>Amantadine for diskynesia in Parkinson's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-20 13:38:02 +0200" MODIFIED_BY="Deirdre Beecher">
<IDENTIFIER MODIFIED="2008-08-20 13:38:02 +0200" MODIFIED_BY="Deirdre Beecher" TYPE="DOI" VALUE="10.1002/14651858.CD003467   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crosby-2003b" MODIFIED="2008-08-20 13:39:56 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Crosby 2003b" TYPE="COCHRANE_REVIEW">
<AU>Crosby N, Deane KHO, Clarke CE.</AU>
<TI>Amantadine in Parkinson's disease.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-20 13:39:56 +0200" MODIFIED_BY="Deirdre Beecher">
<IDENTIFIER MODIFIED="2008-08-20 13:39:56 +0200" MODIFIED_BY="Deirdre Beecher" TYPE="DOI" VALUE="10.1002/14651858.CD003468   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002-A" MODIFIED="2008-08-20 11:11:18 +0200" MODIFIED_BY="Liliana Coco" NAME="Curtin 2002 A" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2131-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002-B" MODIFIED="2008-08-20 11:11:36 +0200" MODIFIED_BY="Liliana Coco" NAME="Curtin 2002 B" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Elbourne D, Altman DG</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2145-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dolin-1982" MODIFIED="2008-08-20 13:44:54 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Dolin 1982" TYPE="JOURNAL_ARTICLE">
<AU>Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J</AU>
<TI>A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<PG>580-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fischer-1999" MODIFIED="2008-08-20 11:11:40 +0200" MODIFIED_BY="Liliana Coco" NAME="Fischer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fischer JS, Rudick, Cutter GR, Reingold SC</AU>
<TI>The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment</TI>
<SO>Multiple Sclerosis</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisk-1994" MODIFIED="2008-08-20 13:51:56 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Fisk 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF</AU>
<TI>Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>18(Suppl.1)</VL>
<PG>S79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flensner-2005" MODIFIED="2008-08-20 13:52:20 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Flensner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Flensner G, Ek AC, Soderhamn O</AU>
<TI>Reliability and validity of the Swedish version of the Fatigue Impact Scale (FIS)</TI>
<SO>Scandinavian Journal of Occupational Therapy</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>170-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-1983" MODIFIED="2008-08-20 11:11:51 +0200" MODIFIED_BY="Liliana Coco" NAME="Hauser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Hauser SL, Dawson DM, Lehrich JR, Bela MF, KevyV, Propper RD, et al</AU>
<TI>Intensive immunosuppression in progressive multiple sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>308</VL>
<NO>4</NO>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-2003" MODIFIED="2008-08-20 13:53:37 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Hauser 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hauser W, Almouhtasseb R, Muthny FA, Grandt D</AU>
<TI>Validation of a German Version of the Fatigue Impact Scale FIS-D</TI>
<TO>Validierung der deutschen Version der Fatigue Impact Scale FIS-D</TO>
<SO>Zeitschrift für Gastoenterologie</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>973-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayden-1996" MODIFIED="2008-08-20 11:12:28 +0200" MODIFIED_BY="Liliana Coco" NAME="Hayden 1996" TYPE="BOOK_SECTION">
<AU>Hayden F</AU>
<TI>Antimicrobial Agents</TI>
<SO>Goodman &amp; Gillman's: The pharmacological basis of therapeutics</SO>
<YR>1996</YR>
<PG>1191-223</PG>
<EN>Ninth</EN>
<ED>Hardman JG, Limbird LE, Molinoff PB, Ruddon RW</ED>
<PB>Mc Graw Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-08-21 10:04:40 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Formulating the problem. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005], Section 4</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 2005)</YR>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-08-20 11:12:33 +0200" MODIFIED_BY="Liliana Coco" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D. Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of Randomised Clinical Trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2006a" MODIFIED="2008-08-20 13:41:04 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Jefferson 2006a" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D.</AU>
<TI>Amantadine and rimantadine for influenza A in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-20 13:41:04 +0200" MODIFIED_BY="Deirdre Beecher">
<IDENTIFIER MODIFIED="2008-08-20 13:41:04 +0200" MODIFIED_BY="Deirdre Beecher" TYPE="DOI" VALUE="10.1002/14651858.CD001169.pub3   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2006b" NAME="Jefferson 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A</AU>
<TI>Antivirals for influenza in healthy adults: systematic review</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<PG>303-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamps-2006" MODIFIED="2008-08-20 14:09:08 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Kamps 2006" TYPE="OTHER">
<AU>Kamps BS, Hoffmann C, Preiser W</AU>
<TI>Influenza Report 2006</TI>
<SO>www.InfluenzaReport.com</SO>
<YR>[accessed 01 May 2006]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kos-2005" NAME="Kos 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kos D, Kerckhofs E, Carrea I, Verza R, Ramos M, Jansa J</AU>
<TI>Evaluation of the Modified Fatigue Impact Scale in four different European countries. Evaluation of the Modified Fatigue Impact Scale in four different European countries</TI>
<SO>Multiple Sclerosis</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>76-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krupp--1997" MODIFIED="2008-08-20 11:12:43 +0200" MODIFIED_BY="Liliana Coco" NAME="Krupp  1997" TYPE="BOOK_SECTION">
<AU>Krupp LB</AU>
<TI>Mechanism, measurement, and management of fatigue in multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>1997</YR>
<ED>Thompson A et al</ED>
<PB>Martin Dunitz</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krupp1989" MODIFIED="2008-08-20 11:12:48 +0200" MODIFIED_BY="Liliana Coco" NAME="Krupp1989" TYPE="JOURNAL_ARTICLE">
<AU>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD</AU>
<TI>The fatigue severity scale: application to patients with Multiple Sclerosis and Systemic Lupus Erythematosus</TI>
<SO>Archives of Neurology</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" MODIFIED="2008-08-20 11:12:52 +0200" MODIFIED_BY="Liliana Coco" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurologic impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005" MODIFIED="2008-08-20 14:10:15 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Lim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lim JK, Wooten D, Siegel R, Cheung RC</AU>
<TI>Amantadine in treatment of chronic hepatitis C virus infection?</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>445-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathiowetz-2003" MODIFIED="2008-08-20 14:10:42 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Mathiowetz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mathiowetz V</AU>
<TI>Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis</TI>
<SO>American Journal of Occupational Therapy</SO>
<YR>2003</YR>
<VL>57</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2001" MODIFIED="2008-08-20 11:13:01 +0200" MODIFIED_BY="Liliana Coco" NAME="McDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>McDonald WI, Compston A, Edan G, Goodkin, Hartung HP, Lublin FD, et al</AU>
<TI>Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>1</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittion_x002d_Vouyovitch06" MODIFIED="2008-08-20 14:11:58 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Pittion-Vouyovitch06" TYPE="JOURNAL_ARTICLE">
<AU>Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H</AU>
<TI>Fatigue in multiple sclerosis is related to disability, depression and quality of life</TI>
<TO>Fatigue in multiple sclerosis is related to disability, depression and quality of life</TO>
<SO>Journal Neurological Sciences</SO>
<YR>2006</YR>
<VL>243</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" MODIFIED="2008-08-20 11:13:09 +0200" MODIFIED_BY="Liliana Coco" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, Mc Donald WI, Davis FA, Ebers GC et al</AU>
<TI>New diagnostic criteria for Multiple Sclerosis: guide-lines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radloff-1977" MODIFIED="2008-08-20 14:32:26 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Radloff 1977" TYPE="JOURNAL_ARTICLE">
<AU>Radloff LS</AU>
<TI>The CES-D Scale: a self-report depression scale for research in the general population</TI>
<SO>Applied Psychological Measures</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>385-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schumacher-1965" MODIFIED="2008-08-20 14:36:08 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Schumacher 1965" TYPE="JOURNAL_ARTICLE">
<AU>Schumacher GA, Beebe G, Kibler RF, kurland LT, Kurtzke JF, McDowell F, et al</AU>
<TI>Problems of experimental trials of therapy in Multiple Sclerosis: Report by the panel of the evaluetion of experimental trials in Multiple Sclerosis</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1965</YR>
<VL>122</VL>
<PG>552-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwab-1972" MODIFIED="2008-08-20 11:13:25 +0200" MODIFIED_BY="Liliana Coco" NAME="Schwab 1972" TYPE="JOURNAL_ARTICLE">
<AU>Schwab RS, Poskanzer DC, England AC, Young RR</AU>
<TI>Amantadine in Parkinson's disease. Review of more than two years experience</TI>
<SO>JAMA: the Journal of the American Medical Association</SO>
<YR>1972</YR>
<VL>222</VL>
<NO>7</NO>
<PG>792-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1993" NAME="Schwartz 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz J, Jandorf L, Krupp LD</AU>
<TI>The measurment of fatigue: a new scale</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>7</NO>
<PG>753-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoof-1992" MODIFIED="2008-08-20 11:13:29 +0200" MODIFIED_BY="Liliana Coco" NAME="Stoof 1992" TYPE="JOURNAL_ARTICLE">
<AU>Stoof JC, Booij J, Drukarch B</AU>
<TI>Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?</TI>
<SO>Clinical Neurology and Neurosurgery</SO>
<YR>1992</YR>
<VL>94 Suppl</VL>
<PG>4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tempelaar-1989" MODIFIED="2008-08-20 14:37:49 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Tempelaar 1989" TYPE="JOURNAL_ARTICLE">
<AU>Tempelaar R, De Haes JC, De Ruiter JH, Bakker D, Van Den Heuvel WJ, Van Nieuwenhuijzen MG</AU>
<TI>The social experiences of cancer patients under treatment: a comparative study</TI>
<SO>Social Science &amp; Medicine</SO>
<YR>1989</YR>
<VL>29</VL>
<PG>635-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-11 10:52:38 +0200" MODIFIED_BY="Liliana Coco">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-09-11 10:45:49 +0200" MODIFIED_BY="Liliana Coco" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-09-11 10:45:49 +0200" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-CMSRG-1987">
<CHAR_METHODS MODIFIED="2008-09-11 10:45:08 +0200" MODIFIED_BY="Liliana Coco">
<P>Multicentre<BR/>Design: RCT crossover<BR/>
<BR/>Duration 10 weeks:<BR/>- 2 weeks run in period<BR/>- 3 weeks first treatment period<BR/>-2 weeks washout period<BR/>-3 weeks second treatment period </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-11 10:45:19 +0200" MODIFIED_BY="Liliana Coco">
<P>11 MS research clinics in Canada<BR/>
<BR/>Patients with definite MS* and moderate to severe daily fatigue<BR/>(&gt; 25 mmon the VAS°).<BR/>- 165 enrolled<BR/>- 115 randomized<BR/>- 86 analysed </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-11 10:45:28 +0200" MODIFIED_BY="Liliana Coco">
<P>amantadine 100 mg b.i.d.<BR/>vs placebo </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-11 10:45:39 +0200" MODIFIED_BY="Liliana Coco">
<P>(1) preferred treatment period (patient and investigator preference at the end of study)<BR/>(2) level of fatigue on VAS (daily and weekly)<BR/>(3) effect on activity most affected by fatigue on VAS<BR/>(4) effect on most bothersome other MS symptom (VAS)<BR/>(5) effect on total score of all 13 activities of daily living (VAS)<BR/>(6) overall evaluation on 5 points scale (patient and investigator assessment)<BR/>(7) EDSS<BR/>(8) BDI<BR/>(9) Side effects<BR/>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-11 10:45:49 +0200" MODIFIED_BY="Liliana Coco">
<P>- 50 patients excluded for insufficient fatigue before randomization (&lt; 25 mm on VAS)<BR/>- 21 patients not analysed for insufficient fatigue after randomization (18%)<BR/>- 8 drop outs (8.5%, 2 patients during amantadine period and 6 during placebo period)<BR/>- Jadad score: 4 </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cohen-1989">
<CHAR_METHODS>
<P>Single centre<BR/>Design: RCT crossover</P>
<P>
<BR/>Duration 10 weeks:<BR/>- 4 + 4 weeks treatment periods <BR/>- 2 weeks washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Departments of Neurology, University of Massachusetts (Worcester) </P>
<P>Patients with probable or definite MS** with daily symptomatic fatigue for at least 3 months, FAI &gt; 80 and EDSS &lt; 6<BR/>- 29 randomized<BR/>- 22 analysed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>amantadine 100 mg b.i.d. <BR/>vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) preferred treatment period<BR/>(at the end of study)<BR/>(2) Daily rating for 7 indices of fatigue on 5 point scale (1-5)<BR/>(3)Neurobehavioral performances (8 neuropsychological tests)<BR/>(4) EDSS<BR/>(5) Side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 7 drop outs (24%, 4 patients during placebo and 3 during amantadine period)<BR/>- Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Krupp-1995">
<CHAR_METHODS>
<P>Multicentre<BR/>Design: RCT parallel</P>
<P>Duration 10 weeks:<BR/>- 2 weeks run in period( fatigue monitoring)<BR/>- 6 weeks treatment period<BR/>- 2 weeks final washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>3 Medical Centres in the New York area</P>
<P>Patients with<BR/>probable or definite MS** <BR/>and FSS score &gt; 4<BR/>- 109 randomized<BR/> - 39 amantadine<BR/> - 27 pemoline<BR/> - 43 placebo<BR/>- 83 analysed (31, 17, 35), <BR/>- 70 analysed (23, 23, 24) for self assessment!<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>amantadine 100 mg b.i.d. <BR/>vs pemoline up to 56.25 mg daily vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Benefit perceived <BR/>(2) MS-FS<BR/>(3) FSS<BR/>(4) RIV<BR/>(5) CES-D<BR/>(6) St Mary Hospital Sleep Questionnaire (modified form)<BR/>(7) EDSS<BR/>(8) Side effects<BR/>(at the end of treatment and 2 weeks later)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- 26 drop outs reported (22%, 8 patients during amantadine, 10 during pemoline and 8 during placebo)<BR/>- not reported self assessment of 49 patients during study and of 53 after washout period<BR/>- not available for analysis comprehensive numerical data for all continuous outcomes <BR/>- Jadad score: 3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rosenberg-1988">
<CHAR_METHODS>
<P>Single centre<BR/>Design: RCT crossover</P>
<P>
<BR/>Duration 3 weeks<BR/>- 1+ 1 week treatment periods <BR/>- 1 week washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Departement of Neurology, University of New Mexico (Albuquerque)</P>
<P>Patients with definite MS and fatigability (anamnestic)<BR/>- 10 randomized<BR/>- 10 analysed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>amantadine 100 mg b.i.d. <BR/>vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Preferred treatment period<BR/>(1-3 weeks)<BR/>(2) faticability scale score <BR/>(0 to 4)<BR/>(3) EDSS<BR/>(4) Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- not available for analysis numerical data for continuous outcomes<BR/>- Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tomassini-2004">
<CHAR_METHODS>
<P>Single centre<BR/>Design: RCT crossover.<BR/>Duration: 3+ 3 week treatment periods <BR/>- 3 week washout period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Department of Neurological Sciences, University of Rome &#8216;&#8216;La Sapienza&#8217;&#8217; - Italy.<BR/>Patients with definite MS** (both relapsing-remitting MS and secondary-progressive MS) with clinical evidence of fatigue as documented by a score &gt;4 on the Fatigue Severity Scale (FSS).<BR/>- 36 randomized<BR/>- 30 analysed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>amantadine 100 mg b.i.d. <BR/>vs acetyl L-carnitine 1g b.i.d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) FSS<BR/>(2) FIS<BR/>(3) BDI<BR/>(4) SEC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>- not available for analysis numerical data for continuous outcomes<BR/>- Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BDI: Beck Depression Inventory (<LINK REF="REF-Beck-1961" TYPE="REFERENCE">Beck 1961</LINK>)<BR/>CES-D: Centre for Epidemiologic Studies Depression Scale - the scores range from 0 to 60 (<LINK REF="REF-Radloff-1977" TYPE="REFERENCE">Radloff 1977</LINK>)<BR/>EDSS: Expanded Disability Status Scale - the scores range from 1.0 to 10.0 (Kurtzke 1983)<BR/>FAI: fatigue assessment inventory - 42 items evaluating fatigue impact on daily living, the final score range from 42 to 168 (for each item score ranges from 1 = not at all to 4 = very representative fatigue) (Cohen 1989)<BR/>FSS: Fatigue Severity Scale - the scores ranges from 1(no fatigue) to 7 (most disabling fatigue) (Krupp 1989)<BR/>MS-FS: Multiple Sclerosis-specific Fatigue Scale - the scores range from 1 to 7 (Schwartz 1993)<BR/>RIV : Rand Index of Vitality - the scale measures energy and the scores range from 4 to 24 (Brooks 1979)<BR/>VAS:50mm Visual Analogue Scale, "no fatigue" in the left of the scale and "as bad as could be" on the right (CMSG 1987)<BR/>FIS: Fatigue Impact Scale (Fisk 1994)<BR/>SEC: Social Experience Checklist (SEC) (<LINK REF="REF-Tempelaar-1989" TYPE="REFERENCE">Tempelaar 1989</LINK>)<BR/>* Schumacher criteria (Schumacher 65)<BR/>** Poser criteria (Poser 83)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-09-11 10:52:38 +0200" MODIFIED_BY="Liliana Coco" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-11 10:52:38 +0200" MODIFIED_BY="Liliana Coco" STUDY_ID="STD-Chiba-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-11 10:52:38 +0200" MODIFIED_BY="Liliana Coco">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geisler-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dual publication (patients considered in Krupp 95)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kemp-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maciejek-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murray-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Plaut-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sailer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only paraclinical measures (abstract)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sailer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only paraclinical measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-11 10:46:26 +0200" MODIFIED_BY="Liliana Coco">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-11 10:46:26 +0200" MODIFIED_BY="Liliana Coco" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-11 10:46:26 +0200" MODIFIED_BY="Liliana Coco" RESULT="YES" STUDY_ID="STD-CMSRG-1987">
<DESCRIPTION>
<P>A </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-21 10:21:23 +0200" MODIFIED_BY="Deirdre Beecher">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Participants included in trials</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>N randomised</P>
</TH>
<TH>
<P>N analyzed</P>
</TH>
<TH>
<P>N excluded</P>
</TH>
<TH>
<P>N drop out (DO)</P>
</TH>
<TH>
<P>% DO/randomised</P>
</TH>
</TR>
<TR>
<TD>
<P>CMSRG 1987</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>9.3*</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosenberg 1988</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Cohen 1989</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>24.1</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupp 1995</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>21.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Amantadine</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Pemoline</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>27.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>18.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Tomassini 2004</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>16.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Amantadine</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>27.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Acetyl L-carnitine</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>\</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>5.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Footnote: *calculated not including 21 patients excluded</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Results of continuous outcomes from studies</TITLE>
<TABLE COLS="9" ROWS="26">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment no.</P>
</TH>
<TH>
<P>Treatment mean</P>
</TH>
<TH>
<P>95% CI - SE* -SD**</P>
</TH>
<TH>
<P>Control no.</P>
</TH>
<TH>
<P>Control mean</P>
</TH>
<TH>
<P>95% CI - SE* -SD**</P>
</TH>
</TR>
<TR>
<TD>
<P>CMSRG 1987</P>
</TD>
<TD>
<P>Weekly fatigue on VAS (fig. 1)§</P>
</TD>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>28.9</P>
</TD>
<TD>
<P>23.3-26.3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>31.6-27.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 1</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.8</P>
</TD>
<TD>
<P>23.2-26.4</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>27.9</P>
</TD>
<TD>
<P>26.3-29.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 2</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.7</P>
</TD>
<TD>
<P>23.1-26.3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>27.0</P>
</TD>
<TD>
<P>25.2-28.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.7</P>
</TD>
<TD>
<P>23.1-26.3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>26.9</P>
</TD>
<TD>
<P>25.3-28.6</P>
</TD>
</TR>
<TR>
<TD>
<P>CMSRG 1987</P>
</TD>
<TD>
<P>Effect on VAS for a selected activity (fig. 2)§</P>
</TD>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>29.3</P>
</TD>
<TD>
<P>27.4-31.2</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>31.8-27.4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 1</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.3</P>
</TD>
<TD>
<P>23.5-27.1</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>27.8</P>
</TD>
<TD>
<P>26.0-29.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 2</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.1</P>
</TD>
<TD>
<P>22.2-26.0</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.6-29.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.1</P>
</TD>
<TD>
<P>22.2-26.0</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>26.8</P>
</TD>
<TD>
<P>25.0-28.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Effects on VAS for 13 ADL (tab 4)§</P>
</TD>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>26.6</P>
</TD>
<TD>
<P>1.13*</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>26.2</P>
</TD>
<TD>
<P>1.06*</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 1</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>0.74*</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>0.74*</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week2</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>23.6</P>
</TD>
<TD>
<P>0.74*</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>0.74*</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Week 3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>24.1</P>
</TD>
<TD>
<P>0.74</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>25.9</P>
</TD>
<TD>
<P>0.74*</P>
</TD>
</TR>
<TR>
<TD>
<P>Cohen 1989</P>
</TD>
<TD>
<P>Diary rating for 7 indices of fatigue on 5 points scale</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>3.18</P>
</TD>
<TD>
<P>0.04*</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>2.96</P>
</TD>
<TD>
<P>0.03*</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupp 1995</P>
</TD>
<TD>
<P>MS-FS (fig.1)§</P>
</TD>
<TD>
<P>baseline</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>5.0</P>
</TD>
<TD>
<P>1.3**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>4.7</P>
</TD>
<TD>
<P>1.9**</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>pre-treat.</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>4.89</P>
</TD>
<TD>
<P>0.23**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>4.68</P>
</TD>
<TD>
<P>0.15**</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>end-treat.</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>0.3**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>4.72</P>
</TD>
<TD>
<P>0.2**</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>FSS (fig.2)§</P>
</TD>
<TD>
<P>baseline</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>0.8**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>0.8**</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>pre-treat.</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>5.62</P>
</TD>
<TD>
<P>0.2**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>5.63</P>
</TD>
<TD>
<P>0.15**</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>end-treat.</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>5.18</P>
</TD>
<TD>
<P>0.25**</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>0.2**</P>
</TD>
</TR>
<TR>
<TD>
<P>Tomassini 2004</P>
</TD>
<TD>
<P>FSS change vs baseline (fig.2)§</P>
</TD>
<TD>
<P>amantadine</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>0.15</P>
</TD>
<TD>
<P>-0.1-0.4</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>acetyl L-carnitine</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>-0.2</P>
</TD>
<TD>
<P>-0.5-0.05</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>washout after amantadine</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>-0.15</P>
</TD>
<TD>
<P>-0.4-0.05</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>washout after acetyl L-carnitine</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>-0.1</P>
</TD>
<TD>
<P>-0.35-0.2</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
<TD>
<P>\\\\\\\\\\\\\\\</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>§ from original articles</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-18 11:57:57 +0200" MODIFIED_BY="Deirdre Beecher">
<APPENDIX ID="APP-01" MODIFIED="2008-09-18 11:57:57 +0200" MODIFIED_BY="Deirdre Beecher" NO="1">
<TITLE MODIFIED="2008-08-21 10:15:16 +0200" MODIFIED_BY="Deirdre Beecher">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-18 11:57:57 +0200" MODIFIED_BY="Deirdre Beecher">
<P>#1"multiple sclerosis"<BR/>#2MeSH descriptor Multiple Sclerosis explode all trees<BR/>#3"Demyelinating disease*"<BR/>#4MeSH descriptor Demyelinating Diseases, this term only<BR/>#5"transverse myelitis"<BR/>#6MeSH descriptor Myelitis, Transverse, this term only<BR/>#7"neuromyelitis optica"<BR/>#8"optic neuritis"<BR/>#9MeSH descriptor Optic Neuritis explode all trees<BR/>#10"encephalomyelitis acute disseminated"<BR/>#11MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only<BR/>#12"devic"<BR/>#13MeSH descriptor Fatigue explode all trees<BR/>#14MeSH descriptor Muscle Fatigue explode all trees<BR/>#15MeSH descriptor Fatigue Syndrome, Chronic explode all trees<BR/>#16fatigue<BR/>#17fatigue AND (syndrome AND chronic)<BR/>#18muscle AND fatigue<BR/>#19MeSH descriptor Amantadine explode all trees<BR/>#20amantadine<BR/>#21amantadin*<BR/>#22symmetrel*<BR/>#23midantan<BR/>#24viregyt<BR/>#25(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)<BR/>#26(#13 OR #14 OR #15 OR #16 OR #17 OR #18)<BR/>#27(#19 OR #20 OR #21 OR #22 OR #23 OR #24)<BR/>#28(#25 AND ( #26 AND #27 ))<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-08-21 10:16:17 +0200" MODIFIED_BY="Deirdre Beecher" NO="2">
<TITLE MODIFIED="2008-08-21 10:15:40 +0200" MODIFIED_BY="Deirdre Beecher">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-21 10:16:17 +0200" MODIFIED_BY="Deirdre Beecher">
<P>(((fatigue) OR (fatigue AND (syndrome AND chronic)) OR (muscle AND fatigue) OR ("Fatigue"[Mesh]) OR ("Muscle Fatigue"[Mesh]) OR ("Fatigue Syndrome, Chronic"[Mesh])) AND (32 OR (amantadine) OR (amantadin*) OR (symmetrel*) OR (midantan) OR (symadine) OR (pymadine) OR (viregyt))) AND (((("Multiple Sclerosis"[mh]) OR ("Myelitis, Transverse"[mh:noexp]) OR ("Demyelinating Diseases"[mh:noexp]) OR ("Encephalomyelitis, Acute Disseminated"[mh:noexp]) OR ("Optic Neuritis"[mh])) OR ((("multiple sclerosis") OR ("neuromyelitis optica") OR ("transverse myelitis") OR (encephalomyelitis) OR (devic) OR ("optic neuritis")) OR ("demyelinating disease*") OR ("acute disseminated encephalomyelitis"))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh])))))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-08-21 10:19:40 +0200" MODIFIED_BY="Deirdre Beecher" NO="3">
<TITLE MODIFIED="2008-08-21 10:19:40 +0200" MODIFIED_BY="Deirdre Beecher">EMBASE (EMBASE.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-21 10:17:16 +0200" MODIFIED_BY="Deirdre Beecher">
<P>((('encephalomyelitis'/exp) OR ('demyelinating disease'/exp) OR ('multiple sclerosis'/exp) OR ('myelooptic neuropathy'/exp) OR ('multiple sclerosis':ti,ab) OR ('neuromyelitis optica':ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND (('crossover procedure'/exp) OR ('double blind procedure'/exp) OR ('single blind procedure'/exp) OR ('randomized controlled trial'/exp) OR (random*:ab,ti) OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR (placebo:ab,ti) OR ('double blind':ab,ti) OR ('single blind':ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti)) AND (('fatigue'/exp) OR ('muscle fatigue'/exp) OR ('chronic fatigue syndrome'/exp) OR (fatigue:ab,ti) OR ('muscle fatigue':ab,ti) OR ('chronic fatigue syndrome':ab,ti)) AND (('amantadine'/exp) OR (amantadine:ab,ti) OR (symmetrel*:ab,ti) OR (viregyt:ab,ti) OR (midantan:ab,ti) OR (amantadin*:ab,ti) OR (pymadine:ab,ti))) AND [humans]/lim AND [embase]/lim</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>